The Center for Immuno-Oncology (CIO) investigates how our immune system reacts to cancer and what we can do to improve tumour immunity. We combine deep fundmental understanding of immunology with preclinical studies to translate new knowledge into clinical trials with the aim of developing new life-saving treatments for a spectrum of cancers.
Oxford’s long history of excellence in immunology is now focused on cancer, and CIO is the hub of the University-wide Oxford Cancer Immuno-Oncology Network (OCION) which links immuno-oncology researchers from multiple disciplines from across the University of Oxford, its affiliated hospitals and industrial partners.
About
CIO supports a spectrum discovery research from atoms to humans with a focus on improving human health.
Read moreWhat's new for Oxford Cancer
-
Oxford Cancer launches 2025 OCION Funding Scheme
13 June 2025
-
OxCODE funding scheme awards 2025
12 June 2025
-
New vaccines that aim to prevent cancer: Starting the conversation
11 June 2025
-
Celebrating two years of the Oxford Cancer Immuno - Oncology Network
11 June 2025
-
New research reveals druggable target arising from chromosomal rearrangement in aggressive leukaemia
10 June 2025
CIO News
Professor Andrew McMichael elected to the US National Academy of Sciences
20 May 2025
The National Academy of Sciences (NAS) in the US announced the election of 120 members and 30 international members in recognition of their distinguished and continuing achievements in original research. Election to membership in the NAS is a mark of excellence in science and is considered one of the highest honours that a scientist can receive.
Oxford Immunology Symposium 2025
3 February 2025
The BSI Oxford Immunology Group, in collaboration with the University of Oxford Immunology Network, is pleased to present a one-day showcase of the fantastic immunology research happening across Oxford.
Agonists and Antagonists in Combined Immunotherapies for Cancer
3 February 2025
Prof. Nacho Melero delivers a talk on Immunotherapies in Cancer for GLOBAL IMMUNOTALKS
Reversing resistance to cancer immune therapy with antibodies
30 January 2025
A new study led by Professor Ignacio Melero of NDM's Centre for Immuno-oncology and the University of Navarra and has highlighted a way to combat resistance to cancer immunotherapy in solid tumours by using antibodies that target GDF-15 protein.
Latest publications
-
Phase II study of perioperative Avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO Study.
Journal article
Alsina M. et al, (2025), Clin Cancer Res
-
Supplemental Figure 2 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplementary Figure S1 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplemental Figure 5 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplemental Figure 3 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
Supplemental Figure 4 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
-
CINs of the cytoplasm: dissecting dsRNA signaling in chromosomal instability.
Journal article
Skolariki A. et al, (2025), Mol Oncol
-
Interactions between cancer-associated fibroblasts and the extracellular matrix in oesophageal cancer.
Journal article
Vadibeler S. et al, (2025), Matrix biology : journal of the International Society for Matrix Biology
-
Immunocytokines and cytokine neutralization for cancer immunotherapy
Journal article
Berraondo P. et al, (2025), Trends in Cancer
-
Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse
Journal article
Heras-Murillo I. et al, (2025), Nature Communications, 16
-
Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies.
Journal article
Galvez-Cancino F. et al, (2025), Immunity
-
Barriers to publishing early phase clinical trials: the oncologists' perspective.
Journal article
Lucassen MJJ. et al, (2025), The oncologist, 30
-
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumors.
Journal article
de Bono JS. et al, (2025), Clinical cancer research : an official journal of the American Association for Cancer Research
-
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases.
Preprint
Lawson NM. et al, (2025)
-
Figure 2 from Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy
Other
Diers AR. et al, (2025)
Oxford Talks
-
Monday, 16 June 2025, 8.45am to 6.45pm
Speakers: Imre Bangha, Prof. Wiebke Denecke, Prof. Thibaut D'Hubert, Prof. Jane Gilbert, Prof. Martin Orwin, Dr Alberto Ravani, Prof. Elizabeth Tyler
Venue: Radcliffe Humanities, Woodstock Road OX2 6GG
-
Monday, 16 June 2025, 10.30am to 6.30pm
Speakers: Professor Rachel Brooks, Professor Agnès van Zanten
Venue: 15 Norham Gardens, 15 Norham Gardens OX2 6PY
-
Monday, 16 June 2025, 11am to 6.30pm
Venue: St Antony's College, 62 Woodstock Road OX2 6JF
-
Monday, 16 June 2025, 11.30am to 12.45pm
Speakers: Luis Garicano
Venue: Manor Road Building, Manor Road OX1 3UQ
-
Monday, 16 June 2025, 11.30am to 12.45pm
Speakers: Luis Garicano
Venue: Manor Road Building, Manor Road OX1 3UQ